Clicky

Atossa Genetics Inc.(ATOS) News

Date Title
Jun 2 Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 5 Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Mar 11 Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Oct 1 Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
Sep 3 Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Aug 30 Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
Aug 28 Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
Jun 25 Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Jun 17 Atossa Set to Join Russell 3000® Index Effective June 28, 2024
Jun 11 Sidoti Events, LLC's Virtual June Small-Cap Conference
Jun 6 Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Jun 5 Atossa to Present at the Sidoti Small-Cap Investor Conference
May 15 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
May 13 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 7 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
Apr 29 Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
Apr 29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
Apr 15 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Apr 11 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Apr 9 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen